Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma
Chase W. Kwon, Rajini K. Murthy, Ragini R. Kudchadkar, Benjamin K. Stoff
Abstract
Immune checkpoint inhibitors, including pembrolizumab, are novel immunotherapeutic agents that have revolutionized cancer therapy. With increasing use of immunotherapy, early recognition and prompt treatment of associated adverse events are critical to ensure patient safety. Cutaneous toxicities are among the most commonly observed adverse events with this class of drugs. Here we report a novel case of lichen planus pemphigoides (LPP) arising in a patient with metastatic Merkel cell carcinoma treated with pembrolizumab.
Topics & Concepts
PembrolizumabMedicineMerkel cell carcinomaDermatologyAdverse effectImmunotherapyMerkel cellSkin cancerSebaceous carcinomaCancerCarcinomaInternal medicineAutoimmune Bullous Skin DiseasesInfectious Diseases and MycologyMycobacterium research and diagnosis